XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Investments and Fair Value Measurements (Tables)
3 Months Ended
Apr. 03, 2022
Fair Value Disclosures [Abstract]  
Schedule of Marketable Securities
Net losses recognized in other expense, net on our marketable equity securities were as follows:
In millionsQ1 2022Q1 2021
Net losses recognized during the period on marketable equity securities$(42)$(72)
Less: Net losses recognized during the period on marketable equity securities sold during the period 14 
Net unrealized losses recognized during the period on marketable equity securities still held at the reporting date$(42)$(58)
Schedule of Hierarchy for Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis:
April 3, 2022January 2, 2022
In millionsLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Money market funds (cash equivalents)$775 $ $ $775 $688 $— $— $688 
Marketable equity securities65   65 107 — — 107 
Helix contingent value right  70 70 — — 65 65 
Deferred compensation plan assets 57  57 — 60 — 60 
Total assets measured at fair value$840 $57 $70 $967 $795 $60 $65 $920 
Liabilities:
Contingent consideration liability$ $ $566 $566 $— $— $615 $615 
Deferred compensation plan liability 54  54 — 56 — 56 
Total liabilities measured at fair value$ $54 $566 $620 $— $56 $615 $671 
Schedule of Changes in Estimated Fair Value of Acquisition Related Contingent Consideration Liabilities
Changes in the estimated fair value of our contingent consideration liability during Q1 2022 were as follows:
In millions
Balance as of January 2, 2022$615 
Change in estimated fair value(49)
Balance as of April 3, 2022(1) (2)
$566 
_____________
(1)As of April 3, 2022, $565 million was included in other long-term liabilities, with remaining balance included in accrued liabilities.
(2)Covered Revenues for Q4 2021 were $10 million, driven primarily by sales of GRAIL’s Galleri test. Covered Revenue Payments in Q1 2022 were approximately $97,000; however, pursuant to the Contingent Value Rights Agreement, the Covered Revenue Payments were applied to reimburse us for certain expenses